68Ga-P3 PET/CT Imaging in Prostate

NCT05940259 · tracked via the Priya Life Science China tracker

Sponsor

Peking University First Hospital

Phase

Not applicable

Started

2023-05-29

Last updated

2024-11-07

Condition(s) studied

Neoplasms

Investigational drug(s) / intervention(s)

[68Ga]P3

[68Ga]P3: 68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.

Study summary

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.

\[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.

Eligibility

Sex

MALE

Min age

18 Years

Max age

75 Years

Healthy volunteers

Accepted

Inclusion Criteria: patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria:

Primary outcome measure(s)

The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate — 1 year
the standardized Uptake Value (SUV) of lesions on 68Ga-P3 PET/CT
The detection efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate — 1 year
the number of lesions detected by 68Ga-P3 PET/CT, based on the pathology or clinical follow-up as gold standard.

Trial sites (1)

Facility	City	Region	Status
Peking University First Hospital	Beijing	Beijing Municipality	Recruiting

More Peking University First Hospital trials in China

Adjuvant Chemotherapy for High Malignant Prostate Cancer Recruiting

Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients Starting soon

FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis Enrolling by invitation

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma Recruiting

Radical Radiotherapy Versus Radical Surgery for UTUC Recruiting

Other trials for the same condition

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC Recruiting

Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation Starting soon

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Active, not recruiting

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Active, not recruiting

Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05940259 on ClinicalTrials.gov ↗ ← All trials in China